OKYO Pharma: Strengthened Leadership and Promising Urcosimod Data Support Reiterated Buy Rating and Upside Potential
I'm PortAI, I can summarize articles.
H.C. Wainwright analyst Yi Chen has reiterated a Buy rating on OKYO Pharma Limited, setting a price target of $7.00. This decision is supported by the appointment of Robert J. Dempsey as a key leader and positive Phase 2 data for urcosimod in treating neuropathic corneal pain. The management transition ensures continuity in development, while encouraging clinical results strengthen the case for the drug's effectiveness. Overall, these factors suggest significant upside potential for shareholders.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments